CARDIFF ONCOLOGY, INC. Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31)
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CARDIFF ONCOLOGY, INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for fiscal 2009 was $1.47M, a 27.95% increase from fiscal 2008.
- CARDIFF ONCOLOGY, INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for fiscal 2008 was $1.15M.
- CARDIFF ONCOLOGY, INC. development stage entities, stock issued, value, issued for cash (deprecated 2015-01-31) for fiscal 2003 was $3.40K.
| Period end | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) 3 month | Development Stage Entities, Stock Issued, Value, Issued for Cash (Deprecated 2015-01-31) 12 month |
|---|---|---|
| 2009-12-31 | $1.47M 10-K · filed 2014-03-17 | |
| 2008-12-31 | $1.15M 10-K · filed 2014-03-17 | |
| 2003-01-31 | $3.40K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |